AP39, A Mitochondrially- Targeted Hydrogen Sulfide Donor, Exerts Protective Effects in Renal Epithelial Cells Subjected to Oxidative Stress in Vitro and in Acute Renal Injury in Vivo. by Ahmad, Akbar et al.
SHOCK-D-15-00284R1 
SHOCK 
 
 
AP39, a mitochondrially- targeted hydrogen sulfide donor, exerts protective effects in renal 
epithelial cells subjected to oxidative stress in vitro and in acute renal injury in vivo 
 
 
Akbar Ahmad1, Gabor Olah1, Bartosz Szczesny1,2, Mark E. Wood3, Matthew Whiteman4 and 
Csaba Szabo1,2* 
 
 
1Department of Anesthesiology, The University of Texas Medical Branch, Galveston, TX, USA, 
2Shriners Hospital for Children, Galveston, TX, USA 
3Department of Biosciences, College of Life and Environmental Science, University of Exeter, 
England 
4University of Exeter Medical School, St. Luke’s Campus, Exeter, England 
 
 
 
Running Title: Renal protective effects of AP39 
 
*Corresponding author:  szabocsaba@aol.com 
  
 
Abbreviations:  AOAA: aminooxyacetic acid; AP39: (10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-
5yl) phenoxy)decyl) triphenylphosphonium bromide; ARF: acute renal failure; CBS: 
cystathionine--synthase (CBS); CSE; cystathionine--lyase; DCF: dichlorofluorescein, GOx: 
glucose oxidase; H2O2: hydrogen peroxide; H2S: hydrogen sulfide; I/R: ischemia/reperfusion; 3-
MST: 3-mercaptopyruvate sulfurtransferase  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
SHOCK-D-15-00284R1 
Abstract 
This study evaluated the effects of AP39 [(10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5yl) 
phenoxy)decyl) triphenyl phosphonium bromide], a mitochondrially targeted donor of hydrogen 
sulfide (H2S) in an in vitro model of hypoxia/oxidative stress injury in NRK-49F rat kidney 
epithelial cells (NRK cells) and in a rat model of renal ischemia-reperfusion injury. Renal 
oxidative stress was induced by the addition of glucose oxidase, which generates hydrogen 
peroxide in the culture medium at a constant rate. Glucose oxidase (GOx)-induced oxidative 
stress led to mitochondrial dysfunction, decreased intracellular ATP content, and, at higher 
concentrations, increased intracellular oxidant formation (estimated by the fluorescent probe 2, 
7-dichlorofluorescein, DCF) and promoted necrosis (estimated by the measurement of lactate 
dehydrogenase release into the medium) of the NRK cells in vitro. Pretreatment with AP39 (30-
300 nM) exerted a concentration-dependent protective effect against all of the above effects of 
GOx. Most of the effects of AP39 followed a bell-shaped concentration-response curve; at the 
highest concentration of GOx tested, AP39 was no longer able to afford cytoprotective effects. 
Rats subjected to renal ischemia/reperfusion responded with a marked increase (over 4-fold over 
sham control baseline) blood urea nitrogen and creatinine levels in blood, indicative of 
significant renal damage. This was associated with increased neutrophil infiltration into the 
kidneys (assessed by the myeloperoxidase assay in kidney homogenates), increased oxidative 
stress (assessed by the malondialdehyde assay in kidney homogenates) and an increase in plasma 
levels of IL-12. Pretreatment with AP39 (0.1, 0.2 and 0.3 mg/kg) provided a dose-dependent 
protection against these pathophysiological alterations; the most pronounced protective effect 
was observed at the 0.3 mg/kg dose of the H2S donor; nevertheless AP39 failed to achieve a 
complete normalization of any of the injury markers measured. The partial protective effects of 
AP39 correlated with a partial improvement of kidney histological scores and reduced TUNEL 
staining (an indicator of DNA damage and apoptosis). In summary, the mitochondria-targeted 
H2S donor AP39 exerted dose-dependent protective effects against renal epithelial cell injury in 
vitro and renal ischemia-reperfusion injury in vivo. We hypothesize that the beneficial actions of 
AP39 are related to the reduction of cellular oxidative stress, and subsequent attenuation of 
various positive feed-forward cycles of inflammatory and oxidative processes. 
 Keywords: oxidative stress, ischemia, renal injury, mitochondria, H2S donor  
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Introduction 
 
 Renal ischemia followed by reperfusion (I/R), caused by circulatory shock of different 
etiologies, or by anesthesia, surgery, or transplantation, is a major cause of acute renal failure 
(ARF). The epithelial cells of the proximal tubule are particularly susceptible to I/R injury, 
leading to acute tubular necrosis, which plays a central part in the pathogenesis of ARF (1,2).  
 Over the last decade hydrogen sulfide (H2S) emerged as an endogenously produced 
gaseous mediator, with anti-inflammatory and cytoprotective properties (3,4). Various H2S 
donation strategies have been developed and tested in vitro and in vivo (5,6), including renal I/R 
injury. The goal of the current study was to evaluate the therapeutic effect of the mitochondrially 
targeted H2S donor AP39 (7,8) in renal epithelial cells subjected to oxidative stress in vitro and 
in a rat model of renal ischemia in vivo. AP39 consists of a mitochondria-targeting motif, 
triphenyl phosphonium (TPP+), coupled to a H2S-donating moiety (dithiolethione) by an 
aliphatic linker. The purpose of the synthesis of this structure is to target H2S delivery to the 
mitochondria, by exploiting the well-known property of TPP+ to accumulate in mitochondria. 
The rationale of targeting the H2S directly into the mitochondria follows recent observations that 
mitochondrial H2S, at low concentrations exerts antioxidant, cytoprotective and stimulatory 
bioenergetic effects (5-9). We hypothesized that in renal oxidative injury, a process well known 
to be associated with mitochondrial dysfunction (10-12), a compound, which targets H2S to 
mitochondria may exert therapeutic effects. The results of our current study show AP39 exerted 
significant and potent cytoprotective effects against hypoxia in vitro and against renal injury in 
vivo.   
 
Materials & Methods 
 
Materials 
 AP39 was synthesized in house as described (7). Other all chemicals were obtained from 
Sigma-Aldrich (St. Louis, MO, USA).  
 
Cell culture 
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 The NRK 49F cell line was purchased from the American Type Culture Collection 
(ATCC CRL#-1570), and cultured in Dulbecco's modified Eagle's medium  (DMEM) containing 
glucose (1 g/l) and sodium pyruvate with 10% FBS, 4 mM L-glutamine adjusted to contain 1.5 
g/l sodium bicarbonate, 100 IU/ml penicillin, 100 μg/ml streptomycin.   
 
In vitro oxidative stress induced by glucose oxidase in the NRK cell model 
 NRK cells (20 × 103 cells per well) were seeded overnight onto 96-well tissue culture 
plates with cell culture medium and cultured at 37°C at 5% CO2 atmosphere for 24 hours. After 
24 hours, the cultured cells were washed with cell culture medium and pretreated with AP39 (30, 
100 or 300 nM) followed by further incubation in the presence of cell culture medium for 30 
minutes. To generate oxidative stress, we used glucose oxidase (GOx) (0.003, 0.03, 0.3 and 3 
U/ml). In one set of studies we have used a short exposure (1 hour); in another set of studies we 
used 1h exposure with GOx, followed by a washout and a further incubation in the presence of 
tissue culture medium for 24 hours. At the end of the experiments, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) viability assays, lactate dehydrogenase (LDH) 
cytotoxicity assay were performed. Cellular adenosine triphosphate (ATP) content and 
intracellular oxidant production was assessed as described below. 
 
MTT assay 
 The MTT method was performed as described (8). Briefly, 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) was added to the cells at a final concentration of 
0.5 mg/ml and cells were cultured at 37 °C for 1h. The cells were washed with PBS and the 
formazan dye was dissolved in DMSO. The amount of converted formazan dye was measured at 
570 nm with a background measurement at 690 nm on a Powerwave reader (Biotek).  
 
LDH assay 
 Measurement of lactate dehydrogenase (LDH) release into the medium (8) was used to 
assess the cytotoxicity of the H2O2 produced by GOx. Briefly, 30 µl of supernatant was saved 
before addition of MTT and mixed with 100 µl freshly prepared LDH assay reagent containing 
85 mM lactic acid, 1 mM nicotinamide adenine dinucleotide (NAD+), 0.27 mM N-methyl 
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phenazonium methyl sulfate (PMS), 0.528 mM 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-
2H-tetrazolium chloride (INT), and 200 mM Tris (pH 8.2). The changes in absorbance were read 
kinetically at 492 nm for 15min (kinetic LDH assay) on a monochromator-based reader 
(Powerwave HT, Biotek) at 37 °C. LDH activity values are shown as Vmax for kinetic assays in 
mOD/min. 
 
Measurement of cellular ATP levels 
 Intracellular ATP concentration was determined by the commercially available CellTiter-
Glo® Luminescent Cell Viability Assay (Promega, Madison, WI, USA) (13). Cells were lysed in 
100 μL Cell Titer-Glo reagent according to the manufacturer’s recommendations, and the 
luminescent signal was recorded for 1s on a high-sensitivity luminometer (Synergy 2; Biotek, 
Winooski, VT, USA). The assay is based on ATP requiring luciferin-oxyluciferin conversion 
mediated by a thermostable luciferase that generates a stable “glow-type” luminescent signal.  
 
2, 7-dichlorofluorescein (DCF) assay 
 Intracellular oxidant production was assessed using a commercially available Reactive 
Oxygen Species (ROS) Detection Reagent (Molecular ProbesTM, Invitrogen detection 
technologies, Eugene, OR, USA). At the end of the experiment, cells were then stained with 10 
µM DCFH-DA for 30 minutes at 37°C and collected. After washing with phosphate-buffered 
saline (PBS), cells were resuspended in PBS followed by the determination of fluorescence 
intensity (λ excitation, 492-495 nm; λ emission, 517-527 nm) as described (14).  
 
In vivo studies  
 All animal investigations confirm to the Guide for the Care and Use of Laboratory 
Animals published by the National Institutes of Health (NIH Publication No. 85-23, Revised 
1985), and was approved by UTMB's local IACUC committee.  
 Male Sprague Dawley rats (12 weeks of age) were housed in a light-controlled room with 
a 12 hour light–dark cycle and were allowed ad libitum access to food and water. Rats were 
anesthetized with ketamine (100 mg/kg i.p.) & dexmedetomidine (0.15 mg/kg i.p.) and 
anesthesia was maintained by supplementary injections of one-third of the initial dose every 30 
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minutes. 
 
Rats were randomly allocated into the following groups: (1) control + vehicle (n = 10); (2) 
I/R+vehicle (n =10); (3) I/R + AP39 (0.1 mg/kg, i.p.) 5 minutes before reperfusion (n = 10); (4) 
I/R+AP39 (0.2 mg/kg, i.p.) 5 minutes before reperfusion (n = 12) and (5) I/R+AP39 (0.3mg/kg, 
i.p.) 5 minutes before reperfusion. The volume of saline (V) administered to the control animals 
was equal to the volume of AP39 administered. 
 The animals were anesthetized as detailed above. After performing a midline laparotomy, 
animals were subjected to bilateral renal ischemia for 30 minutes, during which the renal arteries 
and veins were occluded using microaneurysm clamps. The time of ischemia was set in order to 
maximize the reproducibility of the renal functional impairment while minimizing mortality. 
Treatment groups received vehicle or AP39 (0.1, 0.2 or 0.3 mg/kg) 5 minutes before onset of 
reperfusion. After the renal clamps was removed, the kidneys were observed for a further 5 
minutes to ensure reflow, after which 500 μl of saline at 37°C was injected into the abdomen, and 
the incision was sutured. At 6 hours after reperfusion, animals were euthanized under deep 
anesthesia by using isoflurane (5% inhalation) and death was confirmed by opening of chest. 
Blood and kidneys were collected for evaluation (15). Control animals underwent identical 
surgical procedures but without bilateral renal pedicle clamping and were subjected to all 
procedures used in the other three groups.  
 
Measurement of plasma BUN and creatinine levels 
 At the end of the reperfusion period, rats were sacrificed, and blood samples (1 ml) were 
collected via cardiac puncture. The blood samples (100 microliter) were analyzed by a Vetscan 
analyzer for biochemical parameters (BUN & creatinine) within 1 hour of collection as described 
(16).   
 
Determination of tissue lipid peroxidation using the malondialdehyde assay 
 Tissue malondialdehyde (MDA) levels, an index of cellular injury/oxidative stress (17), 
were detected in kidney samples using a fluorimetric MDA-specific lipid peroxidation assay kit 
(Enzo Life Sciences, Farmingdale, NY, USA) according to the manufacturer’s instructions. The 
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assay is based on the BML-AK171 method in which two molecules of the chromogenic reagent 
N-methyl-2-phenylindole (NMPI) react with one molecule of MDA at 45°C to yield a stable 
carbocyanine dye with a maximum absorption at 586 nm. 
 
Determination of tissue neutrophil infiltration using the myeloperoxidase activity assay 
 Myeloperoxidase activity was measured in kidney samples using a commercially 
available myeloperoxidase (MPO) fluorimetric detection kit (Enzo Life Sciences) (17). The 
assay utilizes a non-fluorescent detection reagent, which is oxidized in the presence of H2O2 and 
MPO to produce its fluorescent analog. The fluorescence was measured at excitation wavelength 
of 530 nm and emission wavelength of 590 nm. 
 
Measurement of plasma cytokine levels 
 Blood from all groups was collected in K2EDTA blood collection tubes and centrifuged 
at 4°C for 15 minutes at 2,000 x g within 30 minutes of collection. Plasma was isolated, 
aliquoted and stored at −80 °C until use. The EMD Millipore’s MILLIPLEX™ MAP Mouse 
cytokine Magnetic Bead Panel 1 kit was used for the quantification of, TNF-, IFN-, GM-CSF, 
IL-1, IL-1, IL-2, IL-4, IL-6, IL-10 and IL-12 (Merck Millipore, Darmstadt, Germany) (16). 
Data analysis was performed using the Luminex xPONENT™ acquisition software (Thermo 
Fisher Scientific, Waltham, MA, USA). 
 
Histological studies and TUNEL assay 
 Kidney biopsies were taken at 6 hours after reperfusion. The biopsies were fixed for 
1 week in buffered formaldehyde solution (10% in PBS) at room temperature, dehydrated by 
graded ethanol and embedded in Paraplast (Sherwood Medical, Mahwah, NJ, USA). Tissue 
sections (thickness: 7 μm) were deparaffinized with xylene stained with hematoxylin/eosin and 
studied using light microscopy. Histological studies were performed in a blinded fashion. In 
the in vivo model, a TUNEL assay was performed by an evaluator who was blinded to the 
treatment animals had received. The TUNEL assay was conducted using a TUNEL detection kit 
(ApopTag Peroxidase In Situ Apoptosis Detection Kit) according to the manufacturer's 
instruction (EMD Millipore, CA, USA). 
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Statistical analysis 
 All values described in the text and figures are expressed as means ± SEM for 
n observations. Student’s t-test, one-way and two-way ANOVA with Tukey’s post hoc test were 
used to detect differences between groups; Prism version 5 for Windows (GraphPad 
Software). p<0.05, p<0.01 were considered statistically significant.  
 
Results 
 
Effect of AP39 on the MTT converting ability of NRK cells exposed to oxidative stress by GOx  
 
 Exposure of the cells to glucose oxidase (0.003, 0.03, 0.3 or 3 U/ml) for 1 hour (Figure 
1A) or, in another set of studies, incubation with glucose oxidase for 1 hour, followed by a 
washout, and followed by a further 24h incubation period (Figure 1B), resulted in a 
concentration-dependent decrease in cellular viability, evidenced by suppressed MTT conversion 
(Figures 1A & B). When lower concentrations of GOx (0.003 U/ml or (0.03 U/ml) were used, 
pretreatment with the lowest concentration of AP39 (30 nM) enhanced the cellular viability of 
the NRK cells; the decrease in MTT conversion in GOx treated cells was attenuated by AP39, 
while elevation of the AP39 concentration to 100 or 300 nM no longer exerted protective effects 
against the GOx induced decreases in MTT conversion, suggestive of a bell-shaped 
concentration-response curve. When a higher concentration of GOx was used (0.3 U/ml), 30 nM 
AP39 failed to protect, while the 'peak' of the bell-shaped concentration-response curve was 
found at the concentration of 100 nM AP39 (Figures 1A & B).  Moreover, AP39-mediated 
protection was only observed at intermediate concentrations of GOx; the protective effects were 
no longer observed against the decrease in MTT conversion elicited by the highest 
concentrations (3 U/ml) of GOx used.   
 
Effect of AP39 on LDH release of NRK cells exposed to oxidative stress by GOx  
 The effect of AP39 was also tested on the breakdown of the integrity of the plasma 
membrane, as measured by LDH release into the extracellular medium, both in the short-term 
exposure to GOx (Figure 2A) as well as in the experiment where GOx exposure was followed by 
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a washout and a 24h further incubation (Figure 2B). AP39 (30, 100 or 300 nM) reduced the 
release of LDH at all concentrations of GOx. When higher concentration of GOx was used (0.3 
U/ml), 30 nM AP39 failed to protect, while the 'peak' of the bell-shaped concentration-response 
curve was found at the concentration of 100 nM AP39 (Figure 2B). The protective effects were 
less pronounced with the highest concentration (300 nM) of AP39, than with the lower 
concentrations, consistent with a bell-shaped concentration-response curve. Interestingly, 
although AP39 failed to protect against the suppression of MTT conversion at the highest flux of 
reactive oxygen species elicited in our study (by the highest concentration of GOx used), the 
results showed that AP39 (most pronouncedly at 30 and 100 nM; less pronouncedly at 300 nM) 
afforded partial protection against the GOx-induced LDH release under the same experimental 
conditions (Figures 2A & B). 
 
Effect of AP39 on the ATP content of NRK cells exposed to oxidative stress by GOx  
 ATP levels in NRK cells exposed to GOx in the presence and absence of AP39 (30-300 
nM) were also determined (Figures 3A & B). AP39 inhibited GOx-induced depletion of ATP. 
However, the protective effects of AP39 on ATP levels were not apparent at the highest 
concentration of GOx employed (3 U/ml). 
 
Effect of AP39 on the intracellular oxidant production in NRK cells exposed to GOx  
 At the two highest concentrations tested, GOx produced a marked increase in DCF 
fluorescence, both in the acute exposure (Figure 4A) and in the GOx exposure/washout/24h 
incubation experiments (Figure 4B). Because in the latter conditions GOx was no longer in the 
medium, DCF fluorescence indicates a secondary, endogenous oxidant production (which was 
triggered by the initial oxidant exposure generated by GOx). AP39 (30, 100 and 300 nM) 
reduced GOx-induced intracellular oxidant production however the ‘bell-shaped’ response 
observed in other assays (e.g. ATP, LDH, MTT) was not observed. 
 
Effect of AP39 on tissue injury in a renal ischemia-reperfusion (I/R) model in rats 
 Renal ischemia (30 minutes), followed by reperfusion (6 hours) significantly impaired 
glomerular function, as evidenced by markedly increased (over 4-fold over sham control 
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baseline) blood urea nitrogen (Figure 5A) and creatinine levels (Figure 5B). Renal I/R damage 
was dose-dependently reduced by AP39; the most pronounced (nevertheless, only partial) 
protection was noted at the 0.3 mg/kg dose of the H2S donor. 
 
Effect of AP39 on renal MPO and MDA levels in a renal ischemia-reperfusion model in rats 
 MDA, an index of oxidative stress, was significantly increased in the renal 
ischemia/reperfusion group, compared to the sham control group; and these increases were 
partially attenuated by pretreatment of the rats with AP39 in dose-dependent manner (Figure 
6A). Similarly, AP39 attenuated renal MPO levels, an index of neutrophil infiltration (Figure 
6B).  
 
Effect of AP39 on plasma cytokine levels in a renal ischemia-reperfusion model in rats 
 Plasma levels of TNF-, IFN-, GM-CSF, IL-1IL-1, IL-2, IL-4, IL-6 and IL-10 were 
unaffected by ischemia-reperfusion, as measured at the end of the experiments (6 hours after 
reperfusion); respective sham-control and post-ischemia-reperfusion values amounted to 
24.2±0.5 and 26.2±2.1 for TNF- 46.3±0.3 and 45.1±0.4 for IFN-, 13.2±0.9 and 14.1±0.5 for 
GM-CSF, 20.1±1.0 and 20.0±1.7 for IL-137.1±1.2 and 35.4±1.7 for IL-1, 54.8±2.3 and 
55.1±3.2 for IL-2, 13.1±0.3 and 13.1±0.6 for IL-4, 20.4±0.9 and 19.9±1.3 for IL-6 and 20.1±1.1 
and 19.3±0.8 for IL-10 (all values in pg/ml; n=10). IL-12 were significantly increased in the 
renal ischemia-reperfusion, group compared to the control group (Figure 7). This increase was 
dose-dependently attenuated by AP39 (Figure 7); most pronouncedly at the 0.3 mg/kg dose of 
the H2S donor. 
 
Effect of AP39 on histopathology and apoptosis of the renal tissue in a renal ischemia-
reperfusion model in rats 
 Hematoxylin and eosin–stained sections are from the outer medulla (representative 
images of at least three experiments), are shown in Figure 8A.  Neutrophil accumulation within 
the interstitium of the kidney was induced by ischemia-reperfusion; this effect was attenuated in 
AP39 (0.3 mg/kg) treated rats. AP39-treated rats subjected to renal I/R, nevertheless, remained to 
show a significant degree of injury (evidenced by a loss of glomerular integrity and swollen 
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epithelium), although to a lesser degree than the degree of injury seen in the I/R group that did 
not receive AP39. In the renal ischemia and reperfusion group TUNEL positive cells were also 
observed in the kidney tissue within 6h and the number of TUNEL positive cells was 
significantly reduced by treatment of the animals with AP39 (0.3 mg/kg) (Figure 8B).   
  
Discussion 
  
 Inhibition of cytochrome C oxidase (mitochondrial Complex IV) is the longest known 
mitochondrial effect of H2S (18). This effect has been proposed to underlie most of the toxic 
effects of high-dose H2S exposure, and it is the prominent mechanism of toxicity in the 
toxicological literature. However, Bouillaud et al. have shown that H2S, at lower concentrations, 
acts as an electron donor to the mitochondria, and serves as an inorganic substrate for 
mitochondrial electron transport (19,20); the phenomenon also exists when H2S is produced by 
endogenous (intramitochondrial) enzymatic sources (21). These effects are intriguing since 
mitochondria endogenously produce H2S under physiological conditions or from CSE (after its 
mitochondrial translocation) in cells exposed to hypoxia (22) or from CBS (for instance in colon 
cancer cells and ovarian cancer cells) (23). Additional mitochondrial stimulatory/protective 
effects of H2S include the stimulation of mitochondrial electron transport via inhibition of 
mitochondrial phosphodiesterase 2A, followed by elevation of intramitochondrial cAMP levels 
(24) and the activation of mitochondrial Complex V (ATP synthase) via sulfhydration (25). In 
addition to these specific reactions, H2S has also been demonstrated to form an overall 
antioxidative protective environment within the mitochondrion, which reduces mitochondrial 
oxidant production, maintains mitochondrial integrity and protects the mitochondria against 
various forms of oxidative stress (26,27). 
 Considering to the above listed beneficial mitochondrial properties of H2S, the idea of 
pharmacological mitochondrial targeting of H2S has emerged in recent years (7,8,28,29). The 
mitochondrially targeted donor AP39 (7) has been shown to increase H2S levels within the 
mitochondrial compartment of endothelial cells (8); has been shown to exert bell-shaped effects 
on mitochondrial electron transport (stimulation at low concentration, followed by inhibition at 
higher concentrations); has been shown to exert protective effects in endothelial cells against 
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oxidative stress, including maintenance of mitochondrial function, protection of mitochondrial 
DNA integrity and inhibition of mitochondrial protein oxidation (8). Moreover, AP39 has been 
shown to exert hemodynamic effects (e.g. reduction in blood pressure) in vivo (28) (consistently 
with the hemodynamic effects of authentic H2S) and has shown potent neuroprotective effects in 
mice after cardiac arrest / CPR at doses 3 orders of magnitude lower than authentic, and non-
mitochondrial, H2S (29). Our current finding that AP39 protected kidney epithelial cells against 
oxidative stress in vitro and protected the kidney against ischemia-reperfusion injury adds to the 
above list of conditions where H2S and, in particular, H2S delivered to mitochondria using a 
TPP+-based approach exerts beneficial effects. Importantly, the dose of the AP39 in the above 
studies is substantially lower than the dose of the 'traditional' non-targeted H2S donors (e.g. 
NaHS) previously shown to exert protective effects. 
 In the in vitro experiments utilizing NRK kidney epithelial cells, four different, but 
related parameters (MTT conversion, LDH release, ATP content and cellular ROS generation) 
were measured, in an acute setting (one hour of glucose oxidase exposure) and in an acute 
exposure/washout/24 hours follow-up setting which may be considered, in some respects, an in 
vitro model of ischemia/reperfusion. The protective effect of AP39 was most apparent at 30 and 
100 nM, which is the same concentration range used by us previously and found to protect 
vascular endothelial cells from oxidative damage, and which was the basis for selecting the 
concentrations to be used for the experimental design of the current study (8). According to 
simplified models of oxidative cell injury, all of the four parameters represent "injury markers" 
(MTT indicates mitochondrial function, LDH indicates the breakdown of cell membrane 
permeability and cell necrosis, ATP levels are decreased when mitochondrial function of the cell 
is impaired, and intracellular oxidants are generated by dysfunctional mitochondria, as well as 
various other sources in a stressed/dying cell). There were some findings that support the above 
outlined simplistic model, and there were some significant differences in the pattern of these 
alterations, and the ability of AP39 to protect against them, that would argue for a more complex 
model. For example, the decreases in cell viability (e.g. measured using the MTT assay) (Figure 
1) are already apparent at GOx concentrations that were not yet able to induce LDH release (an 
indicator of the breakdown of the cell membrane's integrity) (Figure 2), nor intracellular oxidant 
production (Figure 4), nor a significant decrease in cellular ATP content (Figure 3). This finding 
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also indicates that intracellular oxidants, secondary to the initial 1 hour of GOx exposure may not 
be the primary cause of cell death in this model.  
 Overall, the results presented in Figures 1-4 are consistent with the suggestion that the 
effects of AP39 (similar to the effects of authentic H2S in a variety of models) follow a bell-
shaped concentration-response curve; AP39 concentrations of 30 nM and 100 nM exerted most 
of the protective effects, and 300 nM being less effective. In some experimental conditions and 
for some read-out parameters  - e.g. the MTT conversion data shown in Figure 1A, when cells 
were challenged with 0.003 U/ml glucose oxidase - 30 nM AP39 exerted the most protective 
effects, and increasing its concentration was no longer effective. In other experimental conditions 
(e.g. - the MTT conversion data shown Figures 1A &B, when cells were challenged with 0.3 
U/ml, a substantially higher flux of ROS), 30 nM AP39 was not (yet) effective; the protection 
afforded by AP39 peaked at 100 nM, and, once again, further increasing its concentration to 300 
nM was no longer protective. These findings suggest that the effective concentration of AP39, 
while, under our experimental conditions, always tends to be in the low-to-mid nM range. 
However, the actual 'peak' of the bell-shaped curve is a function of the oxidant flux that the cells 
are exposed to. In fact, in some of the experimental conditions, inclusion of AP39 
concentration(s) lower than 30 nM would have been useful to find the lower threshold of the 
protective effect. Nevertheless, taken the totality of the data presented in the current study, as 
well as the results of a previous study conducted in endothelial cells exposed to oxidative stress 
(8) are consistent with the conclusion that AP39 exerts cytoprotective effects at low-to-mid 
nanomolar concentrations and exhibits a bell-shaped concentration-response curve. 
 Interestingly, the marked decrease in MTT conversion at 3 U/ml GOx (the highest 
concentration of GOx used in the current study) and the marked decrease in cellular ATP content 
in the same conditions, would suggest that this high degree of oxidative stress generated under 
such conditions is too overwhelming and no longer influenced by a H2S donor. However, 
interestingly, even at the 3 U/ml GOx concentration, AP39 (most pronouncedly at 100 and 300 
nM) continued to provide a partial protection against the LDH release.  This finding although 
unexpected, indicates that the different viability read-outs (e.g. decreases in MTT being 
indicators of the ROS-mediated suppression of mitochondrial respiration and increases in LDH 
being indicators of the breakdown of cell membrane potential and the start of leaking of the 
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intracellular content to the extracellular space) have a different sensitivity threshold and different 
responsiveness to H2S. We speculate that some amount of H2S, produced by the AP39, may 
reach extramitochondrial (i.e. cytoplasmatic or cell membrane) targets; this is especially likely at 
the high fluxes of GOx, because at these experimental conditions the high ROS flux is likely to 
dissipate the mitochondrial membrane potential (which is the driving force for the accumulation 
of the TPP-targeting groups of AP39 in the mitochondria in the first place). Under such 
conditions, it is conceivable (although remains to be explored) that the H2S that is generated by 
AP39 affects secondary (non-mitochondrial targets), which may contributed to the protection of 
cell membrane integrity. These possibilities and mechanisms remain to be explored in further 
studies. 
 In the in vivo studies, AP39 produced a dose-dependent protective effect against all 
parameters of renal ischemia-reperfusion injury tested (plasma markers of renal dysfunction, 
renal oxidative stress, renal infiltration of mononuclear cells, as well as plasma levels of IL-12). 
These protective effects of AP39 may be related to cytoprotection of the kidney against oxidative 
stress  - a hallmark and significant causative factor in renal ischemia-reperfusion injury (1,2); in 
fact, the protective effect of AP39 against epithelial oxidative injury (present study) and 
endothelial injury (7,8) supports this notion. The exact mechanism by which IL-12 levels are 
reduced by AP39 are not yet clear, but it is possible that AP39 interferes with positive feedback 
cycles of ischemia/reperfusion injury, oxidant production, and pro-inflammatory signaling. The 
pathogenetic role of IL-12 in renal ischemia-reperfusion injury has been studied in several prior 
experiments. For example, IL-12 has been proposed to enhance and upregulate other pro-
inflammatory mediators, which, in turn, would be expected to exacerbate renal dysfunction (30); 
in fact, there is evidence for a Th1/Th2 switched immune response in the pathogenesis of renal 
ischemia-reperfusion injury (30). In addition, neutralization of IL-12 has been shown to exert 
limited protective effects in a renal ischemia-reperfusion model (31,32). Thus, it is likely that IL-
12 is an effector, rather than merely a general marker of renal ischemia-reperfusion injury. It 
remains to be directly tested to what extent the in vivo protection by AP39 in I/R involves 
modulation of IL-12 production, and whether AP39 modulates of Th1/Th2 responses in I/R and 
in other pathophysiological conditions. 
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 The current study, coupled with prior studies showing that exogenous or endogenous H2S 
can protect kidney epithelial cells in vitro and kidney from various forms of ischemic and toxic 
insults in vivo (33-35) supports the view that H2S donation is a potential therapeutic approach to 
preserve renal function.   
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
SHOCK-D-15-00284R1 
Competing interests  
M.W., M.E.W. and the University of Exeter have intellectual property (patent filings) related to 
AP39 and its therapeutic uses. The other authors declare no conflicts of interest in relationship to 
this study. 
 
Authors’ contributions 
 Akbar Ahmad: conduction of experiments, analysis of data, preparation of manuscript; 
Gabor Olah: conduction of experiments, Bartosz Szczesny: conduction of experiments, Matthew 
Whiteman, Mark E. Wood: experimental design, preparation of manuscript; Csaba Szabo: 
experimental design, preparation of manuscript. 
 
 
Acknowledgements  
 This work was supported by the National Institutes of Health (R01GM107846) to C.S.  
 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
SHOCK-D-15-00284R1 
References 
 
[1] Paller MS: The cell biology of reperfusion injury in the kidney. J. Invest. Med. 42:632–
639, 1994.  
[2] Kribben A, Edelstein CL, Schrier RW: Pathophysiology of acute renal failure. J. 
Nephrol. 12:s142–s151, 1999. 
[3]  Szabo C: Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov. 6:917-
935, 2007. 
[4]  Wallace JL, Wang R: Hydrogen sulfide-based therapeutics: exploiting a unique but 
ubiquitous gasotransmitter. Nat. Rev. Drug Discov. 14:329-345, 2015. 
[5]  Szabo C: Medicinal chemistry and therapeutic applications of the gasotransmitters nitric 
oxide, carbon monoxide and hydrogen sulfide. Burger's Medicinal Chemistry. Vol. 5: 
pp. 265-367, 2010. 
[6]   Martelli A, Testai L, Breschi MC, Blandizzi C, Virdis A, Taddei S, Calderone V: 
Hydrogen sulphide: novel opportunity for drug discovery. Med. Res. Rev. 32:1093-1130, 
2012. 
[7] Trionnaire SL, Perry A, Szczesny B, Szabo C, Winyard PG, Whatmore JL, Wood ME, 
Whiteman M: The synthesis and functional evaluation of a mitochondria-targeted 
hydrogen sulfide donor, (10‑oxo‑10-(4-(3‑ thioxo‑3H‑1,2‑dithiol‑5‑yl)nphenoxy) 
decyl)triphenylphosphonium bromide (AP39). Med. Chem. Commun. 5:728–736, 2014. 
[8] Szczesny B, Módis K, Yanagi K, Coletta C, Le Trionnaire S, Perry A, Wood ME, 
Whiteman M, Szabo C: AP39, a novel mitochondria-targeted hydrogen sulfide donor, 
stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the 
loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells in 
vitro. Nitric Oxide. 41:120-130, 2014.  
[9]  Szabo C, Ransy C, Módis K, Andriamihaja M, Murghes B, Coletta C, Olah G, Yanagi 
K, Bouillaud F: Regulation of mitochondrial bioenergetic function by hydrogen sulfide. 
Part I. Biochemical and physiological mechanisms. Br. J. Pharmacol. 171:2099-2122, 
2014.  
[10]  Versteilen AM, Di Maggio F, Leemreis JR, Groeneveld AB, Musters RJ, Sipkema P: 
Molecular mechanisms of acute renal failure following ischemia/reperfusion. Int. J. 
Artif. Organs. 27:1019-1029, 2004. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
SHOCK-D-15-00284R1 
[11]  Tirapelli LF, Bagnato VS, Tirapelli DP, Kurachi C, Barione DF, Tucci S Jr, Suaid HJ, 
Cologna AJ, Martins AC: Renal ischemia in rats: mitochondria function and laser 
autofluorescence. Transplant. Proc. 40:1679-1684, 2008. 
[12]   Hall AM, Rhodes GJ, Sandoval RM, Corridon PR, Molitoris BA: In vivo multiphoton 
imaging of mitochondrial structure and function during acute kidney injury. Kidney Int. 
83:72-83, 2013. 
[13]  Szoleczky P, Módis K, Nagy N, Dóri Tóth Z, DeWitt D, Szabó C, Gero D: Identification 
of agents that reduce renal hypoxia-reoxygenation injury using cell-based screening: 
purine nucleosides are alternative energy sources in LLC-PK1 cells during hypoxia. 
Arch. Biochem. Biophys. 517:53-70, 2012.  
[14]  Brunyanszki A, Olah G, Coletta C, Szczesny B, Szabo C: Regulation of mitochondrial 
poly(ADP-Ribose) polymerase activation by the β-adrenoceptor/cAMP/protein kinase A 
axis during oxidative stress. Mol. Pharmacol. 86:450-462, 2014. 
[15]  Di Paola R, Genovese T, Impellizzeri D, Ahmad A, Cuzzocrea S, Esposito E: 
The renal injury and inflammation caused by ischemia-reperfusion are reduced by 
genetic inhibition of TNF-αR1: a comparison with infliximab treatment. Eur. J. 
Pharmacol. 700:134-146, 2013.   
[16]  Coletta C, Módis H, Oláh G, Brunyánszki A, Herzig DS, Sherwood ER, Ungvári Z, 
Szabo C: Endothelial dysfunction is a potential contributor to multiple organ failure and 
mortality in aged mice subjected to septic shock: preclinical studies in a murine model 
of cecal ligation and puncture. Crit. Care. 18: 511, 2014.  
[17]  Soriano FG, Lorigados CB, Pacher P, Szabó C: Effects of a potent peroxynitrite 
decomposition catalyst in murine models of endotoxemia and sepsis. Shock. 35:560-566, 
2011.  
[18]   Nicholls P, Marshall DC, Cooper CE, Wilson MT: Sulfide inhibition of and metabolism 
by cytochrome c oxidase. Biochem. Soc. Trans. 41:1312-1316, 2013. 
[19]   Goubern M, Andriamihaja M, Nübel T, Blachier F, Bouillaud F: Sulfide, the first 
inorganic substrate for human cells. FASEB J. 21:1699-1706, 2007.  
[20]  Abou-Hamdan A, Guedouari-Bounihi H, Lenoir V, Andriamihaja M, Blachier F, 
Bouillaud F: Oxidation of H2S in mammalian cells and mitochondria. Methods Enzymol. 
554:201-228, 2015. 
[29]   Módis K, Coletta C, Erdélyi K, Papapetropoulos A, Szabo C: Intramitochondrial 
hydrogen sulfide production by 3-mercaptopyruvate sulfurtransferase maintains 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
SHOCK-D-15-00284R1 
mitochondrial electron flow and supports cellular bioenergetics. FASEB J. 27:601-611, 
2013. 
[22]   Fu M, Zhang W, Wu L, Yang G, Li H, Wang R: Hydrogen sulfide (H2S) metabolism in 
mitochondria and its regulatory role in energy production. Proc. Natl. Acad. Sci. USA. 
109:2943-2948, 2012.   
[23]   Szabo C, Coletta C, Chao C, Módis K, Szczesny B, Papapetropoulos A, Hellmich MR: 
Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates 
bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc. Natl. Acad. Sci. 
USA. 110:12474-12479, 2013. 
[24]  Módis K, Panopoulos P, Coletta C, Papapetropoulos A, Szabo C: Hydrogen sulfide-
mediated stimulation of mitochondrial electron transport involves inhibition of the 
mitochondrial phosphodiesterase 2A, elevation of cAMP and activation of protein 
kinase A. Biochem. Pharmacol. 86:1311-1319, 2013. 
[25]  Módis K, Altaany Z, Untereiner A, Yang G, Wu L, Wang R, Szabo C: Hydrogen 
sulfide-induced S-sulfhydration of ATP synthase stimulates mitochondrial bioenergetics. 
Nitric Oxide. 47:S53-S54, 2015. 
[26]   Suzuki K, Olah G, Modis K, Coletta C, Kulp G, Gerö D, Szoleczky P, Chang T, Zhou Z, 
Wu L, Wang R, Papapetropoulos A, Szabo C: Hydrogen sulfide replacement therapy 
protects the vascular endothelium in hyperglycemia by preserving mitochondrial 
function. Proc. Natl. Acad. Sci. USA. 108:13829-13834, 2011. 
[27]   Wen YD, Wang H, Kho SH, Rinkiko S, Sheng X, Shen HM, Zhu YZ: Hydrogen sulfide 
protects HUVECs against hydrogen peroxide induced mitochondrial dysfunction and 
oxidative stress. PLoS One. 8:e53147, 2013. 
[28]  Tomasova L, Pavlovicova M, Malekova L, Misak A, Kristek F, Grman M, Cacanyiova 
S, Tomasek M, Tomaskova Z, Perry A, Wood ME, Lacinova L, Ondrias K, Whiteman 
M: Effects of AP39, a novel triphenylphosphonium derivatised anethole dithiolethione 
hydrogen sulfide donor, on rat haemodynamic parameters and chloride and calcium 
Cav3 and RyR2 channels. Nitric Oxide. 46:131-144, 2015. 
[29]  Ikeda K, Marutani E, Hirai S, Wood ME, Whiteman M, Ichinose F: Mitochondria-
targeted hydrogen sulfide donor AP39 improves neurological outcomes after cardiac 
arrest in mice. Nitric Oxide. In press, 2015. 
 [30]   Marques VP, Gonçalves GM, Feitoza CQ, Cenedeze MA, Fernandes Bertocchi AP, 
Damião MJ, Pinheiro HS, Antunes Teixeira VP, dos Reis MA, Pacheco-Silva A, Saraiva 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
SHOCK-D-15-00284R1 
Câmara NO: Influence of TH1/TH2 switched immune response on renal ischemia-
reperfusion injury. Nephron Exp. Nephrol. 104:e48-e56, 2006. 
[31]   Daemen MA, van't Veer C, Wolfs TG, Buurman WA: Ischemia/reperfusion-induced 
IFN-gamma up-regulation: involvement of IL-12 and IL-18. J. Immunol. 162:5506-
5510, 1999. 
[32]   Köken T, Serteser M, Kahraman A, Akbulut G, Dilek ON: Which is more effective in 
the prevention of renal ischemia-reperfusion-induced oxidative injury in the early period 
in mice: interleukin (IL)-10 or anti-IL-12? Clin. Biochem. 37:50-55, 2004. 
[33]   Tripatara P, Patel NS, Collino M, Gallicchio M, Kieswich J, Castiglia S, Benetti E, 
Stewart KN, Brown PA, Yaqoob MM, Fantozzi R, Thiemermann C: Generation of 
endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal 
ischemia/reperfusion injury and dysfunction. Lab. Invest. 88:1038-1048, 2008.  
[34]  Simon F, Scheuerle A, Gröger M, Stahl B, Wachter U, Vogt J, Speit G, Hauser B, 
Möller P, Calzia E, Szabo C, Schelzig H, Georgieff M, Radermacher P, Wagner F: 
Effects of intravenous sulfide during porcine aortic occlusion-induced kidney 
ischemia/reperfusion injury. Shock. 35:156-163, 2011.  
[35]   Koning AM, Frenay AR, Leuvenink HG, van Goor H: Hydrogen sulfide in renal 
physiology, disease and transplantation-the smell of renal protection. Nitric Oxide. 
46:37-49, 2015. 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
SHOCK-D-15-00284R1 
Figure legends 
 
Figure 1. Effect of AP39 on the viability of oxidatively stressed NRK cells. AP39 (30 nM, 
100 nM or 300 nM) pretreatment enhances cellular recovery after 1h (A) & 24h (B) of GOx 
exposure (0.003, 0.03, 0.3 or 3U/ml) on NRK cells, followed by the measurement of MTT 
conversion. There is a decrease in MTT conversion in GOx treated cells; these effects are 
attenuated by AP39. Data (% of vehicle-treated control values) are shown as mean ± SEM values 
from three independent experiments with 4–8 replicates for each end-point. * p<0.05, ** p<0.01 
shows a significant decrease in MTT in response to GOx treatment (in the GOx treated group 
that also received AP39 vehicle, compared to the to baseline control in the absence of GOx or 
AP39). # p<0.05, ## p<0.01 shows a significant enhancement of MTT by AP39, when compared 
to its vehicle control in the presence of the same concentration of GOx.  
 
Figure 2. Effect of AP39 on LDH release of oxidatively stressed NRK cells. Cells were 
exposed to glucose oxidase (0.003, 0.03, 0.3 or 3U/ml) for 1h (A), in another set exposed to 1h 
followed by a washout and replacement of the medium with fresh tissue culture medium and 
incubated for a subsequent 24h (B), followed by the measurement of LDH conversion. There is 
an increase in LDH content of the medium of GOx treated cells; these effects are attenuated by 
AP39 (30 nM, 100 nM and 300 nM). Data are shown as mean ± SEM values from three 
independent experiments with 4–8 replicates for each end-point; values are expressed as the 
maximum LDH release observed at 3 U/ml GOx. * p<0.05, ** p<0.01 shows a significant 
increase in LDH release in response to GOx treatment (in the GOx treated group that also 
received AP39 vehicle, compared to the to baseline control in the absence of GOx or AP39). # 
p<0.05, ## p<0.01 shows a significant reduction of LDH by AP39, when compared to its vehicle 
control at the same concentration of GOx.   
 
Figure 3. Effect of AP39 on cellular ATP levels of oxidatively stressed NRK cells. NRK cells 
were subjected to 1h (A) and 24h (B) GOx exposure (0.003, 0.03, 0.3& 3U/ml). Cells were 
pretreated with AP39 (30 nM, 100 nM or 300 nM) 30 min prior to GOx exposure. AP39-
mediated protection was observed at intermediate concentrations of GOx. Data (% of vehicle-
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treated control values) are shown as mean ± SEM values from three independent experiments 
with 4–8 replicates for each end-point. * p<0.05, ** p<0.01 shows a significant decrease in ATP 
levels in response to GOx treatment, (in the GOx treated group that also received AP39 vehicle, 
compared to the to baseline control in the absence of GOx or AP39). # p<0.05, ## p<0.01 shows 
a significant enhancement of ATP levels by AP39, when compared to its corresponding control 
at the same concentration of GOx.  
 
Figure 4. Effect of AP39 on DCF production of oxidatively stressed NRK cells. Increase in 
DCF fluorescence in response to exposure of GOx for 1h (A) and 24h (B) incubation in tissue 
culture medium of NRK cells is shown. Pretreatment with AP39 30 min prior to GOx exposure 
observed concentration dependent protective effect. Data are shown as mean ± SEM values from 
three independent experiments with 4–8 replicates for each end-point; values are expressed as 
the maximum DCF production observed at 3 U/ml GOx. * p<0.05, ** p<0.01 shows a significant 
increase in DCF fluorescence in response to GOx treatment, when compared to baseline control 
(in the absence of GOx or AP39). # p<0.05, ## p<0.01 shows a significant reduction of DCF 
fluorescence by AP39, when compared to its corresponding control at the same concentration of 
GOx.   
  
Figure 5. Effect of AP39 on BUN and creatinine plasma levels in a renal ischemia-
reperfusion model in the rat. Renal I/R significantly impaired glomerular function, as 
evidenced by markedly increased (over 4-fold over sham control baseline) blood urea nitrogen 
(A) and creatinine levels (B); this increase was concentration-dependently reduced by AP39; 
most pronouncedly at the 0.3 mg/kg dose of the H2S donor. Data are shown as mean ± SEM of 
10 animals; *p<0.05 show significant increases in the vehicle-treated I/R group, compared to the 
sham control; # p<0.05 shows a significant protective effect of AP39 in I/R compared to the I/R 
group treated with AP39 vehicle. 
 
Figure 6. Effect of AP39 on MPO and MDA levels in a renal ischemia-reperfusion model in 
the rat. Renal I/R significantly increased renal MPO (A) and renal MDA levels (B); this increase 
was concentration-dependently reduced by AP39; most pronouncedly at the 0.3 mg/kg dose of 
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the H2S donor. Data are shown as mean ± SEM of 10 animals; *p<0.05 show significant 
increases in the vehicle-treated I/R group, compared to the sham control; # p<0.05 shows a 
significant protective effect of AP39 in I/R compared to the I/R group treated with AP39 vehicle. 
 
Figure 7. Effect of AP39 on plasma IL-12 levels in a renal ischemia-reperfusion model in 
the rat. Renal I/R significantly increased plasma IL-12 levels; this increase was concentration-
dependently reduced by AP39; most pronouncedly at the 0.3 mg/kg dose of the H2S donor. Data 
are shown as mean ± SEM of 10 animals; *p<0.05 show significant increases in the vehicle-
treated I/R group, compared to the sham control; # p<0.05 shows a significant protective effect 
of AP39 in I/R compared to the I/R group treated with AP39 vehicle. Data are shown as mean ± 
SEM of 10 animals. 
 
Figure 8. Effect of AP39 on histopathology and apoptosis in a renal ischemia-reperfusion 
model in the rat. Hematoxylin and eosin–stained sections are from the outer medulla are shown 
in (A); TUNEL staining is shown in (B). Top figures represent representative sham controls; 
middle figures represent vehicle-treated rats subjected to renal I/R; bottom figures represent an 
AP39 (0.3 mg/kg) treated rat subjected to renal I/R. Please note that neutrophil accumulation 
within the interstitium of the kidney, as well as the intensity of TUNEL staining was 
significantly reduced by AP39, but neither the histological damage, nor the TUNEL staining was 
completely normalized by AP39 treatment. Each group shows 3 representative animals of n=10 
animals. 
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